Contact Us
  Search
The Business Research Company Logo
Artificial Pancreas Device System Market Report 2026
Published :July 2026
Pages :250
Format :PDF
Delivery Time :2-3 Business Days
Why 2-3 days? We update the report with the latest data and news before delivery. Let us know if you need us to expedite.
Report Price :$4,490.00

Artificial Pancreas Device System Market Report 2026

Global Outlook – By Device Type (Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems), By Treatment Type (Bi-Hormonal, Insulin Only, Hybrid), By End-User (Hospitals, Medical Centers, Other End-Users) - Market Size, Trends, Strategies, and Forecast to 2030

Artificial Pancreas Device System Market Overview

• Artificial Pancreas Device System market size has reached to $2.06 billion in 2025 • Expected to grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.7% • Growth Driver: Impact Of Increasing Pancreatic Cancer Prevalence On The Artificial Pancreas Device System Market • Market Trend: Innovations in Automated Insulin Delivery Systems • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Pancreas Device System Market?

Artificial pancreas device system (APDS) is a medical technology designed to automate blood glucose control for individuals with diabetes. The system integrates continuous glucose monitoring (CGM) with an insulin pump, and uses a sophisticated algorithm to automatically adjust insulin delivery based on real-time glucose readings. The device aims to mimic the glucose-regulating function of a healthy pancreas, thereby reducing the need for manual blood glucose monitoring and insulin injections, and helping to maintain blood glucose levels within a target range. The main types of devices in the artificial pancreas device system market are threshold suspend device systems, control-to-range systems, and control-to-target systems. Threshold suspend device systems refer to insulin pump technologies used in diabetes management that automatically suspend insulin delivery when blood glucose levels drop below a predefined threshold. The various treatment types include bi-hormonal, insulin only, and hybrid, and several end-users including hospitals, medical centers, and others.
Artificial Pancreas Device System Market Global Report 2026 Market Report bar graph

What Is The Artificial Pancreas Device System Market Size and Share 2026?

The artificial pancreas device system market size has grown rapidly in recent years. It will grow from $2.06 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to increasing prevalence of diabetes, early adoption of insulin pump technologies, expansion of continuous glucose monitoring usage, improvements in medical sensor accuracy, growing awareness of automated diabetes management.

What Is The Artificial Pancreas Device System Market Growth Forecast?

The artificial pancreas device system market size is expected to see rapid growth in the next few years. It will grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing demand for fully automated glucose regulation, rising investments in digital diabetes care, expansion of remote patient monitoring, growing focus on personalized insulin therapy, increasing regulatory support for advanced diabetes devices. Major trends in the forecast period include increasing adoption of closed-loop glucose control systems, rising integration of cgm with insulin pumps, growing use of predictive algorithms for insulin delivery, expansion of wearable diabetes management devices, enhanced focus on patient-centric automation.
Research Expert

Book your 30 minutes free consultation with our research experts

Top Market Segments Chart For Artificial Pancreas Device System Market Showing Segment-Wise Market Share Distribution.

Global Artificial Pancreas Device System Market Segmentation

1) By Device Type: Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems 2) By Treatment Type: Bi-Hormonal, Insulin Only, Hybrid 3) By End-User: Hospitals, Medical Centers, Other End-Users Subsegments: 1) By Threshold Suspend Device Systems: Insulin Pump with Threshold Suspend, Continuous Glucose Monitoring (CGM) Integrated Systems 2) By Control-To-Range Systems: Hybrid Closed-Loop Systems, Insulin Delivery Systems with Range Control, Real-Time Glucose Adjustment Systems 3) By Control-To-Target Systems: Fully Closed-Loop Artificial Pancreas Systems, Insulin Pumps with Targeted Glucose Control, Automated Glucose Regulation Systems

What Is The Driver Of The Artificial Pancreas Device System Market?

The increasing prevalence of pancreatic cancer is expected to propel the growth of the artificial pancreas device system market going forward. Pancreatic cancer is a malignant tumor that originates in the pancreas, a gland located behind the stomach. Pancreatic cancer is influenced by a combination of lifestyle, genetic, medical, and environmental factors, along with genetic mutations causing hereditary pancreatitis, which can lead to chronic inflammation of the pancreas. An artificial pancreas device system (APDS) is primarily designed to help individuals with diabetes manage their blood sugar levels by automatically monitoring glucose and delivering the appropriate amount of insulin. For instance, in March 2024, Cancer Australia, a government agency, estimated that 4,506 new cases of pancreatic cancer were diagnosed in 2023, an increase from the 3,751 cases reported over the past five years. Therefore, the increasing prevalence of pancreatic cancer is driving the growth of the artificial pancreas device system industry.

Key Players In The Global Artificial Pancreas Device System Market

Major companies operating in the artificial pancreas device system market are Medtronic plc, Abbott Laboratories, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Roche Diabetes Care, Ypsomed, SOOIL Development, Beta Bionics Inc., Bigfoot Biomedical Inc., Diabeloop SA, Inreda Diabetic B.V., Defymed SAS, DreaMed Diabetes Ltd., Medtrum Technologies Inc., EOFlow Co. Ltd., Cellnovo, Pancreum Inc., Admetsys Corporation, GlucoModicum, MicroTech Medical
CompetitorMarketShareAnalysisaltname

This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.

Bubble Chart Of Company Scoring Matrix By Innovation, Brand And Revenue For The Artificial Pancreas Device System Market

This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.

Explore how leading companies compare across key metrics in our report Get Report

What Are Latest Mergers And Acquisitions In The Artificial Pancreas Device System Market?

In September 2023, Abbott Laboratories, a US-based pharmaceutical company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition enhances Abbott's footprint in diabetes care by leveraging its world-leading Freestyle Libre portfolio of continuous glucose monitoring technology. It also advances the company's mission to create connected solutions that make diabetes management more personalized and precise. Bigfoot Biomedical is a US-based company that specializes in developing prototype of automated insulin delivery systems, known as artificial pancreas,
Market Analysis Map Highlighting Largest Region For Artificial Pancreas Device System Market

Regional Outlook

North America was the largest region in the artificial pancreas device system market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Need data for a specific geography? Request Regional Data

What Defines the Artificial Pancreas Device System Market?

The artificial pancreas device system market includes revenues earned by entities by providing services such as patient monitoring, device maintenance, data management, software updates, healthcare provider consultations, and training and support for patients and healthcare professionals. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial pancreas device system market also includes sales of insulin pumps, continuous glucose monitors, control algorithms and software applications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Market Attractiveness Scoring And Analysis Chart Evaluating Growth, Competition, Risk Factors For The Artificial Pancreas Device System Market

This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.

Total Addressable Market Analysis Chart Displaying Revenue Potential And Market Size For The Artificial Pancreas Device System Market

This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.

Access full TAM calculations and growth projections in our report Get Report

What Key Data and Analysis Are Included in the Artificial Pancreas Device System Market Report 2026?

The artificial pancreas device system market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial pancreas device system industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Artificial Pancreas Device System Market Report Forecast Analysis

Report Attribute Details
Market Size Value In 2026$2.35 billion
Revenue Forecast In 2030$3.92 billion
Growth RateCAGR of 13.7% from 2026 to 2030
Base Year For Estimation2025
Actual Estimates/Historical Data2020-2025
Forecast Period2026 - 2030
Market RepresentationRevenue in USD Billion and CAGR from 2026 to 2030
Segments CoveredDevice Type, Treatment Type, End-User
Regional ScopeAsia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country ScopeThe countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
Key Companies ProfiledMedtronic plc, Abbott Laboratories, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Roche Diabetes Care, Ypsomed, SOOIL Development, Beta Bionics Inc., Bigfoot Biomedical Inc., Diabeloop SA, Inreda Diabetic B.V., Defymed SAS, DreaMed Diabetes Ltd., Medtrum Technologies Inc., EOFlow Co. Ltd., Cellnovo, Pancreum Inc., Admetsys Corporation, GlucoModicum, MicroTech Medical
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options
Chat with us